Drug intelligence / Profile preview

volociximab + gemcitabine

Development stage: Unknown
Lead developer: PDL BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Volociximab + gemcitabine is an investigational combination therapy consisting of **volociximab**, a chimeric monoclonal antibody targeting the α5β1 integrin involved in tumor angiogenesis, and **gemcitabine**, a nucleoside analog chemotherapeutic agent. Volociximab works by binding to and inhibiting α5β1 integrin, thereby blocking the establishment of new blood vessels (angiogenesis) necessary for tumor growth. Gemcitabine inhibits DNA synthesis in rapidly dividing cells. This combination has been evaluated in metastatic pancreatic cancer for its safety and efficacy in enhancing anti-tumor effects[2][3].

Targets

ITGA5:ITGB1 (Integrin α5β1)DNA polymerase familyRNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on volociximab + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on volociximab + gemcitabine.

Explore the full profile